MedTrace Logo

Endometrial Cancer Recurrence in Patients Taking Metformin

NCT05192850 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2025-03-28

No results posted yet for this study

Summary

Given the early literature available and its biological plausibility as an inhibitor of the mammalian target of rapamycin (mTOR) protein, it is hypothesized that women with endometrial cancer who take metformin for non-cancer related reasons have a lower cancer recurrence rate compared to women not taking metformin. The primary goal of this study is to determine whether metformin use is associated with a decrease in the rate of endometrial cancer recurrence. Secondary objectives are to assess whether women with endometrial cancer taking metformin have longer progression free survival and overall survival than those that do not take metformin.

Conditions

  • Recurrent Endometrial Carcinoma

Interventions

DRUG

Metformin use

As an observational study, this is past exposure to metformin that occurred during the study period

Sponsors & Collaborators

  • WellSpan Health

    lead OTHER

Principal Investigators

  • Eav Lim, DO · WellSpan Health-York Cancer Center

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-12-27
Primary Completion
2023-02-27
Completion
2023-02-27
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05192850 on ClinicalTrials.gov